On June 24, 2021 Gliknik Inc., an immunology company dedicated to patients with cancer and autoimmune disorders, reported that it has successfully completed an $11.5 million Series C Preferred Stock financing (Press release, Gliknik, JUN 24, 2021, View Source [SID1234584333]). First In Ventures (FIV) led the Series C with SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings also participating. The proceeds are targeted to progress the growing pipeline of Gliknik product candidates. Gliknik has secured $81 million to date to advance its programs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We believe that Gliknik has created several potential best-in-class mid-stage assets," said Scott Roth, managing partner of FIV. "This capital will help unlock the potential of these compounds and uniquely positions Gliknik to make a difference for patients with cancer or autoimmune disorders."
Funding will help advance Gliknik clinical and pre-clinical programs, including:
A randomized double-blind, placebo-controlled phase 2 study of Gliknik immuno-oncology compound biropepimut-S, which is nearing completion. Clinicians are assessing two-year endpoints in the prevention-of-recurrence of high-risk squamous cell oral cavity cancer.
Gliknik immune modulating compound GL-2045, a recombinant mimetic of pooled human IVIG, which is a potent clinical candidate under active development by Gliknik licensee Pfizer for autoimmune diseases. Gliknik believes that based on potency, purity and anticipated convenience, GL-2045 has the potential to be a disruptive advance for autoimmune diseases that could help address the current critical shortage of IVIG.
GL-0719 is a new type of complement modulator, which is designed to control diseases while leaving critical host defense systems intact. GL-0719 is poised to enter a phase 1 trial in 2021.
Other compounds in preclinical development
Kyle Rusconi, a founder of FIV, is joining the Gliknik Board. "During the last several years, Gliknik has created a significant pipeline of important compounds," said Mr. Rusconi. "This scientific development was done in a capital-efficient manner that preserved shareholder equity."
"We are humbled by the depth of support from our investor base and welcome the addition of discerning investors with a long-term view," said Gliknik CEO David Block.